Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06312176
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-03-07
Brief Title:
A Study of Sacituzumab Tirumotecan MK-2870 as a Single Agent and in Combination With Pembrolizumab MK-3475 Versus Treatment of Physicians Choice in Participants With HRHER2- Unresectable Locally Advanced or Metastatic Breast Cancer MK-2870-010
Sponsor:
Organization:
Merck Sharp Dohme LLC
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
1200
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: